Professor Honglin Wang Was Elected as the First Vice Chairman of the Skin Immunization Branch of the Chinese Society of Immunology

Link of the original article:

https://www.shgh.cn/Content/News/14996

On August 26, the inaugural meeting and the first academic annual meeting of the Skin Immunization Branch of the Chinese Society of Immunology were officially held. At the meeting, Professor Honglin Wang, executive vice president of the Institute for Clinical Research of Shanghai General Hospital and director of the Precision Research Center for Refractory Disease, was elected as the first vice chairman of the Skin Immunization Branch of Chinese Society of Immunology.

The Skin Immunization Branch of China Society of Immunology aims to develop and strengthen the research team of skin immunology, improve the research level of skin immunology, and expand international influence. The conference brought together basic immunologists and clinical dermatologists in basic and clinical research area. Professors from Chinese Academy of Engineering, Chinese Academy of Sciences, Peking Union Medical College of the Chinese Academy of Medical Sciences, and Chinese Society of Immunology gave lectures. The contents closely followed the current research hotspots and academic trends, It covers frontier innovative scientific advances such as new mechanisms of immune and inflammatory regulation and spatio-temporal omics research, protein molecular Atlas of single cancer cell, progress and challenges of immunotherapy, development and treatment of immune related diseases based on traditional Chinese medicine, and acquired immune characteristics of novel coronavirus naturally infected people.

The conference demonstrated the new progress and achievements in academic research in the field of skin immunology in China, and also built a high-level academic exchange platform for further promoting interdisciplinary intersection and integration innovation in this field.

Honglin Wang, principal investigator and doctoral supervisor, is the executive vice president of the Institute for Clinical Research of Shanghai General Hospital and the director of the Precision Research Center for Refractory Disease, winner of the National Science Fund for Distinguished Young Scholars in 2017, Chief scientist of the key R & D program of the Ministry of Science and Technology in 2020, distinguished professor of Shanghai Jiaotong University, PI, and subject leader. Shanghai Eastern Scholar and Pujiang Talent. In 2015, he was awarded the Excellent Academic Leader of Shanghai, and served as the vice chairman of the Skin Immunization Branch of China Society of Immunology, the vice chairman of the Immunology Society of China Association of Chinese Medicine, and the Deputy Leader of the Experiment Division, The Chinese Society of Dermatology, Chinese Medicine Association.

He has been engaged in the research of immunologic mechanism and new therapeutic targets of psoriasis for a long time, and has achieved innovative research results. His related work has been published in 66 international academic journals such as immunity, science advances, EMBO molecular medicine, nature communications, etc., with a total impact factor (if) of 300, cited for about 3000 times, and obtained 11 national invention patents and 4 PCT patents. Since the establishment in 2009, his team has received a total of 9 grants, including one 2020 National Key R&D Program (Chief Scientists), Ministry of Science and Technology, one National Natural Science Foundation of China Distinguished Young Scholars fund, one original exploration project of the National Natural Science Foundation of China, two key programs of the National Natural Science Foundation of China, one subproject of the National Program on Key Basic Research Project of China (973 Program), one major research program (cultivation) of the National Natural Science Foundation of China, and two general programs of the National Natural Science Foundation of China. In addition, 10 municipal, bureau level and university level scientific research projects including Shanghai Excellent Academic Leader, Shanghai Shenkang Hospital Development Center Projects, Shanghai Pujiang Talent Program, STAR Program of Shanghai Jiao Tong University, and Shanghai Jiao Tong University Integration and Innovation Fund were also approved.

In the field of translational medicine, Prof. Honglin Wang’s team focused on the research and development of innovative drugs in the field of psoriasis treatment. It took nearly 20 years to modify and screen the structure of the active ingredients of Chinese traditional medicine frankincense, and obtained a new compound entity ckba. This small molecule candidate drug is a "First-in-Class" candidate new drug for psoriasis independently developed in China and with independent intellectual property rights in the world. It obtained the clinical trial license on April 15, 2019, and successfully completed the phase I clinical trial in Shanghai General Hospital. It has carried out phase II clinical trials and expanded the indications for vitiligo.

Correspondent: Zhenyao Xu. Clinical Translational Center